

PUFAs and NSAIDs inhibit lung cancer metastatic process through Rho GTPase signaling

Lauren E. Perry¹, Hailey M. York¹, Rosemary A. Poku², Jamie K. Alan³, and Felix Amissah^{1,*}

¹Ferris State University, College of Pharmacy, Big Rapids, MI 49307, USA; perry16@ferris.edu; yorh1@ferris.edu; amissaf@ferris.edu; ²College of Medicine, Central Michigan University, Mt. Pleasant, MI, 48859, USA; poku1@cmich.edu; ³Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA; alanjam1@msu.edu * Correspondence: amissaf@ferris.edu; Tel: (+1-231-591-3790 (F.A.)

ABSTRACT


Objective
Ras-related C3 botulinum toxin substrate (Rac1) and Cell division control protein 42 (Cdc42) GTPases play critical roles in cancer cell metastasis. Omega-3 polyunsaturated fatty acids (PUFAs) and non-steroidal anti-inflammatory drugs (NSAIDs) show anticancer activities through diverse molecular mechanisms. We have already demonstrated that combining NSAIDs with PUFAs was more effective at altering the expression of critical proteins in the RAS/MEK/ERK and PI3K/Akt pathways. We studied the ability of selected NSAIDs and omega-3 PUFAs combination to inhibit lung cancer cell invasion and determine their impact on Rho GTPase signaling in the metastatic process.

Methods
We conducted western blotting to detect Rho GTPases (RhoA, Rac1, and Cdc42) in A549, NCI-H1299, and NCI-H1975 cells after exposure to PUFAs and NSAIDs. We further examined the effect of co-treatment on NSCLC cell migration and invasion. Western blot analysis detected the expression of marker proteins in EMT.

Results
Exposure of A549, H1975, and H1299 cells to DHA, EPA or E-EPA, and diclofenac or ketorolac resulted in suppression of both the distance of migration, the number of cells that migrated into the wounded and cell invasion. Furthermore, co-treatment with DHA and diclofenac disrupted actin filament assembly and inhibited cell migration and invasion. In addition, the co-treatment resulted in altered expression of Rho GTPases and the marker proteins involved in EMT by increasing expression of the epithelial marker, E-cadherin, while downregulating the expressions of mesenchymal markers, N-cadherin, Fibronectin and Vimentin, ZEB1, and β -catenin.


Conclusions
The data from this study demonstrate that co-treatment with PUFAs and low-dose NSAIDs suppressed NSCLC cell motility and invasion, is associated with inhibition of the Rho GTPase activity and provides more significant anticancer potential in preventing or controlling NSCLC metastasis.

BACKGROUND




METHODS


Migration assay: Wound healing assay was used to assess the inhibitory potential of PUFAs and NSAIDs on lung cancer cell migration.




Matrigel invasion assay: was used to assess the inhibitory potential of PUFAs and NSAIDs on lung cancer cell invasion.



Western blotting analysis: was conducted on lung cancer cells exposed to PUFAs and NSAIDs.



G-LISA™ GTPase Activation Assay: was conducted on lung cancer cells exposed to PUFAs and NSAIDs.



Immunofluorescence: Treated A549 cells were fixed, permeabilized and stained with DAPI and fluorescein-phalloidin or anti-Rac1 or RhoA antibody. The fluorescent images obtained with Nikon Eclipse Ci microscope coupled to QImaging QClick™ digital camera.



RESULTS




Figure 1. PUFAs and NSAIDs decreased the (A) expression and (B) activation of RhoA, Rac1, and Cdc42 in A549 and H1975.




Figure 2. PUFAs and NSAIDs decrease RhoA, Rac1, and Cdc42 activity. A GTPase effector-binding assay was used to measure Rho GTPase activities in A549 cell lysates.




Figure 4. PUFAs and NSAIDs inhibit the invasion of multiple lung cancer cell lines. Co-treatment of DHA with diclofenac inhibited NSCLC cell invasion of A549, H1299, and H1975 cells






Figure 5. PUFAs and NSAIDs disrupt F-actin organization in A549 cells. Co-treatment with DHA and diclofenac disrupts F-actin organization in A549 cells.

CONCLUSIONS

Co-treatment with PUFAs and low-dose NSAIDs

- ↓ Rho GTPase levels and activation in cells
- disrupting actin cytoskeleton organization
- ↓ cell migration and invasion
- ↓ EMT



REFERENCES

Amissah, F. et al. Regulation of polyisoprenylated methyl ester by polyunsaturated fatty acids and prostaglandins. *Eur J Lipid Sci Technol* 2011; 113(11): 1321-1331.

Lambert, A.W. et al., 2017. Emerging Biological Principles of Metastasis. *Cell* 168, 670–691.

Molist E. et al., 2017. Rho GTPase signaling in cancer progression and dissemination. *Physiol Rev* 2022 Jan 1;102(1):455-510.

Pijuan J. et al., 2019. In vitro Cell Migration, Invasion, and Adhesion Assays: From Cell Imaging to Data Analysis. *Front Cell Dev Biol.* 2019 Jun 14;7:107.

Poku RA et al., 2020. Diclofenac Enhances Docosahexaenoic Acid-Induced Apoptosis in Vitro in Lung Cancer Cells. *Cancers (Basel)*. 2020 Sep 20;12(9):2683.

Poku R. et al., 2023. PI3K Functions Downstream of Cdc42 to Drive Cancer phenotypes in a Melanoma Cell Line. *Small GTPases*. 2023 Dec;14(1):1-13.

Porter A.P., Papaioannou A., Malliri A. Deregulation of Rho GTPases in cancer. *Small GTPases*. 7(3):123-38.

Sanookpan K. et al., 2021. Ovalitinone Inhibits the Migration of Lung Cancer Cells via the Suppression of AKT/mTOR and Epithelial-to-Mesenchymal Transition. *Molecules*. 2021 Jan 26;26(3):638.